Expect significant downward pressure on the stock as the new shares are issued at $0.325, effectively flooding the market. The warrants create overhang pending stockholder approval. Monitor for the shareholder vote on the warrants and any subsequent 8-K filings for closing details. The heavy dilution suggests further equity raises may be needed, given the company's cash burn and lack of revenue.
Price Chart
Executive Summary
AIM ImmunoTech announced a heavily dilutive registered direct offering of 7,519,351 shares at $0.325/share, raising ~$2.4M in gross proceeds, with a concurrent private placement of Series I warrants to purchase up to 15,038,702 additional shares. The offering represents roughly 81% dilution of current outstanding shares and, if warrants are exercised, could more than triple the share count. The deal closes May 21, 2026, and proceeds are earmarked for clinical supply manufacturing, Phase 3 trial activities, and working capital.
Key Financial Metrics
Key Facts
- Registered direct offering of 7,519,351 shares at $0.325/share, gross proceeds ~$2.4M
- Concurrent private placement of Series I warrants to purchase up to 15,038,702 shares at $0.325, exercisable subject to stockholder approval, expiring 5 years from exercise date
- Offering expected to close May 21, 2026; Ladenburg Thalmann acting as placement agent
- Proceeds to be used for clinical drug supply manufacturing, Phase 3 trial activities, and working capital
- Estimated pre-offering shares outstanding ~9.2M based on $3M market cap and $0.325 price; new shares represent ~81% dilution
- Company is pre-revenue, clinical-stage biotech; no approved products
Financial Impact
Gross proceeds of $2.4M against a $3M market cap; ~81% dilution from the offering alone, with potential for further dilution if warrants exercised (up to 15M additional shares)
Risk Factors
- Severe immediate dilution from the offering and potential further dilution from warrant exercise
- Company is pre-revenue with no approved products, relying on continued financing for clinical trials
- Stockholder approval for warrants may not be obtained, but the base offering is already dilutive
- Clinical trial risks: Ampligen Phase 3 may fail or be delayed, depleting cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298826 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers